vs
ANI PHARMACEUTICALS INC（ANIP）とPOWER SOLUTIONS INTERNATIONAL, INC.（PSIX）の財務データ比較。上の社名をクリックして会社を切り替えられます
ANI PHARMACEUTICALS INCの直近四半期売上が大きい（$247.1M vs $191.2M、POWER SOLUTIONS INTERNATIONAL, INC.の約1.3倍）。ANI PHARMACEUTICALS INCの純利益率が高く（11.1% vs 8.4%、差は2.7%）。POWER SOLUTIONS INTERNATIONAL, INC.の前年同期比売上増加率が高い（32.5% vs 29.6%）。ANI PHARMACEUTICALS INCの直近四半期フリーキャッシュフローが多い（$29.1M vs $-7.6M）。過去8四半期でPOWER SOLUTIONS INTERNATIONAL, INC.の売上複合成長率が高い（41.7% vs 34.1%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
アダニ・エナジー・ソリューションズ株式会社（旧称：アダニ送電株式会社）は電力の送配電事業を営む企業で、本社はアフマダーバードに所在します。2025年4月時点で累計26,696回路キロメートルの送電網を運用しており、インド最大級の民間部門送電会社の1つです。
ANIP vs PSIX — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $191.2M |
| 純利益 | $27.5M | $16.1M |
| 粗利率 | — | 21.9% |
| 営業利益率 | 14.1% | 12.7% |
| 純利益率 | 11.1% | 8.4% |
| 売上前年比 | 29.6% | 32.5% |
| 純利益前年比 | 367.5% | -31.0% |
| EPS（希薄化後） | $1.14 | $0.69 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $191.2M | ||
| Q3 25 | $227.8M | $203.8M | ||
| Q2 25 | $211.4M | $191.9M | ||
| Q1 25 | $197.1M | $135.4M | ||
| Q4 24 | $190.6M | $144.3M | ||
| Q3 24 | $148.3M | $125.8M | ||
| Q2 24 | $138.0M | $110.6M | ||
| Q1 24 | $137.4M | $95.2M |
| Q4 25 | $27.5M | $16.1M | ||
| Q3 25 | $26.6M | $27.6M | ||
| Q2 25 | $8.5M | $51.2M | ||
| Q1 25 | $15.7M | $19.1M | ||
| Q4 24 | $-10.3M | $23.3M | ||
| Q3 24 | $-24.2M | $17.3M | ||
| Q2 24 | $-2.3M | $21.5M | ||
| Q1 24 | $18.2M | $7.1M |
| Q4 25 | — | 21.9% | ||
| Q3 25 | — | 23.9% | ||
| Q2 25 | — | 28.2% | ||
| Q1 25 | — | 29.7% | ||
| Q4 24 | — | 29.9% | ||
| Q3 24 | — | 28.9% | ||
| Q2 24 | — | 31.8% | ||
| Q1 24 | — | 27.0% |
| Q4 25 | 14.1% | 12.7% | ||
| Q3 25 | 15.9% | 13.9% | ||
| Q2 25 | 6.6% | 16.9% | ||
| Q1 25 | 13.3% | 18.2% | ||
| Q4 24 | -2.3% | 17.5% | ||
| Q3 24 | -13.8% | 16.3% | ||
| Q2 24 | 3.7% | 22.9% | ||
| Q1 24 | 14.8% | 11.2% |
| Q4 25 | 11.1% | 8.4% | ||
| Q3 25 | 11.7% | 13.5% | ||
| Q2 25 | 4.0% | 26.7% | ||
| Q1 25 | 8.0% | 14.1% | ||
| Q4 24 | -5.4% | 16.1% | ||
| Q3 24 | -16.3% | 13.8% | ||
| Q2 24 | -1.7% | 19.5% | ||
| Q1 24 | 13.2% | 7.5% |
| Q4 25 | $1.14 | $0.69 | ||
| Q3 25 | $1.13 | $1.20 | ||
| Q2 25 | $0.36 | $2.22 | ||
| Q1 25 | $0.69 | $0.83 | ||
| Q4 24 | $-0.45 | $1.01 | ||
| Q3 24 | $-1.27 | $0.75 | ||
| Q2 24 | $-0.14 | $0.94 | ||
| Q1 24 | $0.82 | $0.31 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | $41.3M |
| 総負債低いほど良い | — | $96.6M |
| 株主資本純資産 | $540.7M | $178.6M |
| 総資産 | $1.4B | $424.7M |
| 負債/資本比率低いほどレバレッジが低い | — | 0.54× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | $41.3M | ||
| Q3 25 | $262.6M | $49.0M | ||
| Q2 25 | $217.8M | $49.5M | ||
| Q1 25 | $149.8M | $50.0M | ||
| Q4 24 | $144.9M | $55.3M | ||
| Q3 24 | $145.0M | $40.5M | ||
| Q2 24 | $240.1M | $28.8M | ||
| Q1 24 | $228.6M | $33.1M |
| Q4 25 | — | $96.6M | ||
| Q3 25 | — | $96.7M | ||
| Q2 25 | — | $1.8M | ||
| Q1 25 | — | $1.0M | ||
| Q4 24 | — | $184.0K | ||
| Q3 24 | — | $238.0K | ||
| Q2 24 | — | $292.0K | ||
| Q1 24 | — | $345.0K |
| Q4 25 | $540.7M | $178.6M | ||
| Q3 25 | $505.8M | $162.5M | ||
| Q2 25 | $436.8M | $135.7M | ||
| Q1 25 | $418.6M | $84.3M | ||
| Q4 24 | $403.7M | $65.3M | ||
| Q3 24 | $405.9M | $42.1M | ||
| Q2 24 | $455.8M | $24.8M | ||
| Q1 24 | $452.0M | $3.2M |
| Q4 25 | $1.4B | $424.7M | ||
| Q3 25 | $1.4B | $458.9M | ||
| Q2 25 | $1.3B | $437.7M | ||
| Q1 25 | $1.3B | $372.7M | ||
| Q4 24 | $1.3B | $328.2M | ||
| Q3 24 | $1.3B | $339.1M | ||
| Q2 24 | $920.8M | $307.6M | ||
| Q1 24 | $914.5M | $286.8M |
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.60× | ||
| Q2 25 | — | 0.01× | ||
| Q1 25 | — | 0.01× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.01× | ||
| Q2 24 | — | 0.01× | ||
| Q1 24 | — | 0.11× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $-4.6M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | $-7.6M |
| FCFマージンFCF / 売上 | 11.8% | -4.0% |
| 設備投資強度設備投資 / 売上 | 0.5% | 1.6% |
| キャッシュ転換率営業CF / 純利益 | 1.10× | -0.29× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | $14.1M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $-4.6M | ||
| Q3 25 | $44.1M | $3.3M | ||
| Q2 25 | $75.8M | $16.7M | ||
| Q1 25 | $35.0M | $8.8M | ||
| Q4 24 | $15.9M | $32.7M | ||
| Q3 24 | $12.5M | $12.6M | ||
| Q2 24 | $17.4M | $1.5M | ||
| Q1 24 | $18.3M | $15.6M |
| Q4 25 | $29.1M | $-7.6M | ||
| Q3 25 | $38.0M | $1.7M | ||
| Q2 25 | $71.8M | $14.6M | ||
| Q1 25 | $32.5M | $5.4M | ||
| Q4 24 | $13.5M | $30.0M | ||
| Q3 24 | $7.7M | $12.1M | ||
| Q2 24 | $13.0M | $822.0K | ||
| Q1 24 | $13.7M | $14.8M |
| Q4 25 | 11.8% | -4.0% | ||
| Q3 25 | 16.7% | 0.8% | ||
| Q2 25 | 34.0% | 7.6% | ||
| Q1 25 | 16.5% | 4.0% | ||
| Q4 24 | 7.1% | 20.8% | ||
| Q3 24 | 5.2% | 9.7% | ||
| Q2 24 | 9.4% | 0.7% | ||
| Q1 24 | 10.0% | 15.6% |
| Q4 25 | 0.5% | 1.6% | ||
| Q3 25 | 2.7% | 0.8% | ||
| Q2 25 | 1.9% | 1.1% | ||
| Q1 25 | 1.3% | 2.5% | ||
| Q4 24 | 1.3% | 1.8% | ||
| Q3 24 | 3.2% | 0.3% | ||
| Q2 24 | 3.2% | 0.6% | ||
| Q1 24 | 3.3% | 0.9% |
| Q4 25 | 1.10× | -0.29× | ||
| Q3 25 | 1.66× | 0.12× | ||
| Q2 25 | 8.87× | 0.33× | ||
| Q1 25 | 2.23× | 0.46× | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | 0.73× | ||
| Q2 24 | — | 0.07× | ||
| Q1 24 | 1.00× | 2.20× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PSIX
| Energy End Market | $153.4M | 80% |
| Industrial End Market | $33.3M | 17% |
| Transportation End Market | $4.6M | 2% |
